MeSH Browser

MeSH Heading: Ramucirumab
Tree Number(s): D12.776.124.486.485.114.224.060.866; D12.776.124.790.651.114.224.060.866; D12.776.377.715.548.114.224.200.866
Unique ID: D000096662
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D000096662
Scope Note: A humanized monoclonal antibody and antagonist of VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 (VEGFR2).
Entry Term(s): 1121B; Cyramza; IMC 1121B; IMC-1121B; IMC1121B; LY3009806
Pharm Action: Angiogenesis Inhibitors
Public MeSH Note: 2024; RAMUCIRUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2009-2023
History Note: 2024 (2009)
Date Established: 2024/01/01
Date of Entry: 2023/07/26
Revision Date: 2023/05/17

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Immunoproteins [D12.776.124.486]
      - Immunoglobulins [D12.776.124.486.485]
        
        Antibodies [D12.776.124.486.485.114]
        
        Antibodies, Monoclonal [D12.776.124.486.485.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
        
        Abciximab [D12.776.124.486.485.114.224.060.125]
        
        Adalimumab [D12.776.124.486.485.114.224.060.250]
        
        Alemtuzumab [D12.776.124.486.485.114.224.060.313]
        
        Basiliximab [D12.776.124.486.485.114.224.060.344]
        
        Bevacizumab [D12.776.124.486.485.114.224.060.375]
        
        Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
        
        Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
        
        Cetuximab [D12.776.124.486.485.114.224.060.750]
        
        Daclizumab [D12.776.124.486.485.114.224.060.766]
        
        Denosumab [D12.776.124.486.485.114.224.060.782]
        
        Gemtuzumab [D12.776.124.486.485.114.224.060.790]
        
        Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
        
        Ipilimumab [D12.776.124.486.485.114.224.060.798]
        
        Natalizumab [D12.776.124.486.485.114.224.060.813]
        
        Nivolumab [D12.776.124.486.485.114.224.060.829]
        
        Omalizumab [D12.776.124.486.485.114.224.060.844]
        
        Palivizumab [D12.776.124.486.485.114.224.060.860]
        
        Panitumumab [D12.776.124.486.485.114.224.060.864]
        
        Ramucirumab [D12.776.124.486.485.114.224.060.866]
        
        Ranibizumab [D12.776.124.486.485.114.224.060.868]
        
        Trastuzumab [D12.776.124.486.485.114.224.060.875]
        
        Ustekinumab [D12.776.124.486.485.114.224.060.937]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Serum Globulins [D12.776.124.790]
      - Immunoglobulins [D12.776.124.790.651]
        
        Antibodies [D12.776.124.790.651.114]
        
        Antibodies, Monoclonal [D12.776.124.790.651.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
        
        Abciximab [D12.776.124.790.651.114.224.060.125]
        
        Adalimumab [D12.776.124.790.651.114.224.060.250]
        
        Alemtuzumab [D12.776.124.790.651.114.224.060.375]
        
        Basiliximab [D12.776.124.790.651.114.224.060.407]
        
        Bevacizumab [D12.776.124.790.651.114.224.060.438]
        
        Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
        
        Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
        
        Cetuximab [D12.776.124.790.651.114.224.060.750]
        
        Daclizumab [D12.776.124.790.651.114.224.060.766]
        
        Denosumab [D12.776.124.790.651.114.224.060.782]
        
        Gemtuzumab [D12.776.124.790.651.114.224.060.790]
        
        Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
        
        Ipilimumab [D12.776.124.790.651.114.224.060.798]
        
        Natalizumab [D12.776.124.790.651.114.224.060.813]
        
        Nivolumab [D12.776.124.790.651.114.224.060.829]
        
        Omalizumab [D12.776.124.790.651.114.224.060.844]
        
        Palivizumab [D12.776.124.790.651.114.224.060.860]
        
        Panitumumab [D12.776.124.790.651.114.224.060.864]
        
        Ramucirumab [D12.776.124.790.651.114.224.060.866]
        
        Ranibizumab [D12.776.124.790.651.114.224.060.868]
        
        Trastuzumab [D12.776.124.790.651.114.224.060.875]
        
        Ustekinumab [D12.776.124.790.651.114.224.060.937]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Globulins [D12.776.377]
    - Serum Globulins [D12.776.377.715]
      - Immunoglobulins [D12.776.377.715.548]
        
        Antibodies [D12.776.377.715.548.114]
        
        Antibodies, Monoclonal [D12.776.377.715.548.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
        
        Abciximab [D12.776.377.715.548.114.224.200.125]
        
        Adalimumab [D12.776.377.715.548.114.224.200.250]
        
        Alemtuzumab [D12.776.377.715.548.114.224.200.375]
        
        Basiliximab [D12.776.377.715.548.114.224.200.407]
        
        Bevacizumab [D12.776.377.715.548.114.224.200.438]
        
        Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
        
        Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
        
        Cetuximab [D12.776.377.715.548.114.224.200.750]
        
        Daclizumab [D12.776.377.715.548.114.224.200.766]
        
        Denosumab [D12.776.377.715.548.114.224.200.782]
        
        Gemtuzumab [D12.776.377.715.548.114.224.200.790]
        
        Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
        
        Ipilimumab [D12.776.377.715.548.114.224.200.798]
        
        Natalizumab [D12.776.377.715.548.114.224.200.813]
        
        Nivolumab [D12.776.377.715.548.114.224.200.829]
        
        Omalizumab [D12.776.377.715.548.114.224.200.844]
        
        Palivizumab [D12.776.377.715.548.114.224.200.860]
        
        Panitumumab [D12.776.377.715.548.114.224.200.864]
        
        Ramucirumab [D12.776.377.715.548.114.224.200.866]
        
        Ranibizumab [D12.776.377.715.548.114.224.200.868]
        
        Trastuzumab [D12.776.377.715.548.114.224.200.875]
        
        Ustekinumab [D12.776.377.715.548.114.224.200.937]

Ramucirumab Preferred

IMC 1121B Narrower

Concept UI: M0538911
Terms: IMC 1121B Preferred Term
Term UI T757418
Date09/08/2009
LexicalTag LAB
ThesaurusID NLM (2009); 1121B
Term UI T000966349
Date08/23/2019
LexicalTag LAB
ThesaurusID NLM (2020); IMC-1121B
Term UI T757419
Date09/08/2009
LexicalTag LAB
ThesaurusID NLM (2009); IMC1121B
Term UI T757420
Date09/08/2009
LexicalTag LAB
ThesaurusID NLM (2009)

Cyramza Narrower

LY3009806 Narrower

Ramucirumab MeSH Descriptor Data 2024